# Compass says depression drug has long-lasting benefits

> **Open Intelligence Dossier** · First detected: 2026-07-07 23:07 UTC · Category: Business

## Executive Summary
Compass Pathways' psilocybin depression therapy shows six‑month durability, sparking market optimism.

## Intelligence Brief
Compass Pathways reported six‑month results from its second Phase 3 trial of the psilocybin‑based compound COMP006, indicating a rapid and durable effect in treating depression. Coverage highlights the positive data, noting share price gains and the company’s plan to seek a launch in the first half of 2027.


Business Wire, Moomoo, Psychedelic Alpha, Endpoints News and STAT all reported on the trial outcomes and the upcoming year‑end filing. Next steps include the anticipated year‑end regulatory filing and a potential H1 2027 market launch, according to the statements in the reports.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Business Wire | Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile | [Source Link](https://news.google.com/rss/articles/CBMi8wFBVV95cUxNVkFqbkxFeVV3bzNBeHhodHIxYUliZ3E2WlVpanpHUEdpQjR4NUstQ2N6dHp0Q0RDZi1ycXJDVlhkeV9uUmtZXzNSZk1pdFUzNVpkOFNaZVdmb2RiODdjLVNrUHl4YlZraTNWRktfVzZWMUZXZUxRcU9PckVJVlQtZ2M5OURscXItU3ZsakZSVjBlUHdaN3FjNDBXbnEzWE1BZUpublpscEFPMy05U2VGdGFha0xRV2U4UjJYbmw4SG8zY3U4Rkk1SVpkQU15ODVoLTBsdW1YNnhZWnczUUFmM2l0dzdnTktGeW1ISkZUMEpPMk0?oc=5) |
| Moomoo | Compass Pathways Shares Gain on Positive Late-Stage Trial Data for Depression Treatment | [Source Link](https://news.google.com/rss/articles/CBMipwFBVV95cUxNdklZaUM0aHA5MWVwemZMd3VtQ0JQQUUzd3lFZjlndnYtLTBnbENvNjhpLXhUX1F2ME43aml6Tkc4M2J1OHF3WEI3R1hLT2QzM3pmdW03T0VXZmFob1lyNGIzTC1kMkVOeEdEeWM1VWJrcUU4U1doYmF6X0laNzVMYlJkcWpZT3VZNTQ2aVFaV1dUVUhzejVFT2hVc2hUVFN3OVRWYTZBaw?oc=5) |
| Psychedelic Alpha | Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch | [Source Link](https://news.google.com/rss/articles/CBMipwFBVV95cUxQd3d4ckQ3VUFFdGF5OGlieUNURkpSNEhiWGh5bVdBRU1Vc3ctbjh6ZlpqNHZSVFlUSTUyeU5kQV83eUp1MFEyejZLd3kzUFJVX2QxalZnT2ZnWnUwM1dNRVU2WGcyMnVRd2lXQ00yeF9FR2U4cHdrUDhDZHJfelk4TS0wazZqZ0hjTlhBSklXalNiMmpHcHZlZTA4S2dQTFZaMnNMMHVobw?oc=5) |
| Endpoints News | Updated: Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing | [Source Link](https://news.google.com/rss/articles/CBMisgFBVV95cUxQLXQtUFJ6RWRvZWFHR3lYX0dPcE1oMDZya2tQVWVHdmtJSjQ5M21oOEVqUFNSUE1mMXh2VURzck5xdDNrdmZ0eW45ZDRGRWVlZTRQTGcxdEl4YWxlSWFRcmdycV9oSG5DZXk2bmo2Tzl4RWx1Zkt6cFg4MWx1UVM0Rmt3TVVrLTV1bmdYaDE3VVh1bVUxSTVDcHozU0hyYTQxQWZ4dDR0RXFxRzJTV0lBR1pn?oc=5) |
| STAT | Compass says depression drug has long-lasting benefits | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSW1qNjBQWWF2VFZyQjZ6MWd2bUFEVUVSOXFwVy1DM05uOGczanhCTFBiaVlpY2xrVWh3cWM4LXZJY1g2Z3BEQ0UzMGpBa25BaUhKbGpSWW1LN1VMdm1GNTB0dF9QQlQtWDRBRGFJZ1VzX2lETUtyS3ZIX3VuQkx5MFpWYW5YYk5hMy0yQktvNkdSamwtQnRJcVFNUnlDeUIza0Nid0hCVF8tVW8?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-07-07/compass-says-depression-drug-has-long-lasting-benefits*